02096 SIMCERE PHARMA
Closed Add to Porfolio| Key Financial Ratio (Fiscal Year: 12/2025) | |||
| Current | 2.21X | Oper Margin | 20.8% |
|---|---|---|---|
| LT Debt/Equity | 0.8% | Net Margin | 17.4% |
| Total Debt/Equity | 12.6% | Return on Equity | 14.3% |
| Price/Book | 3.38X | Return on Assets | 9.1% |
| (HKD 13.620) | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
| Net Profit (MHKD) | 1,496.02 | 767.85 | 787.81 | 1,043.69 | 1,843.33 |
|---|---|---|---|---|---|
| Net Profit Growth (%) | +94.8 | -2.5 | -24.5 | -43.4 | +132.0 |
| Earnings Per Share (HKD) | 0.603 | 0.306 | 0.302 | 0.4 | 0.707 |
| Earnings Per Share Growth (%) | +97.3 | +1.2 | -24.4 | -43.4 | +112.8 |
| Dividend Per Share (HKD) | 0.200 | 0.175 | 0.176 | 0.176 | 0.176 |
| P/E* (X) | 22.59 | 44.57 | 45.10 | 34.08 | 19.28 |
| Yield (%) | 1.47 | 1.28 | 1.29 | 1.29 | 1.29 |
| Dividend Share (%) | 33.24 | 57.20 | 58.18 | 43.98 | 24.87 |
| Book NAV (HKD) | 4.034 | 3.003 | 3.026 | 3.006 | 2.996 |
| Auditors' Opinion | N/A | Unqualified | Unqualified | Unqualified | Unqualified |
Remarks:
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
Last Update Time: 2026-04-02 21:40:20
Latest Result
| (RMBMn) | 2025-12 | 2024-12 | Chg* (%) | 2023-12 |
| Cover Period (mths) | 12 | 12 | NA | 12 |
|---|---|---|---|---|
| Turnover | 7,731 | 6,635 | +16.5 | 6,608 |
| Operating Result | 1,515 | 808.054 | +87.5 | -59.73 |
| Associates | -1.11 | 2.162 | -151.3 | 7.844 |
| Profit Before Taxation | 1,514 | 808.715 | +87.2 | 740.038 |
| Taxation | 170.322 | 86.713 | +96.4 | 26.088 |
| Profit /( Loss) After Taxation | 1,344 | 722.002 | +86.1 | 713.95 |
| Minority Interests | 0 | 0 | N/A | -0.811 |
| Net Profit | 1,344 | 722.002 | +86.1 | 714.761 |
| Earnings Per Share () | 0.6029 | 0.3056 | +97.3 | 0.3020 |
| Dividend Per Share () | 0.2004 | 0.1748 | +14.6 | 0.1757 |
| Announcement Date | 2026-03-25 | 2025-03-24 | NA | 2024-03-20 |
* Annualised
Last Update Time: 2026-04-02 21:40:25
